newsfilter
← Latest News
GlobeNewswire·

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

  • BioAtla, Inc. (NASDAQ: BCAB) announced a conference call & webcast to discuss third quarter 2025 financial results & business highlights.
  • The event is scheduled for Thursday, November 13, 2025, at 4:30 p.m. ET.
  • The financial press release will be available prior to the call in the "News Releases" section of the company website.
  • A replay of the call will be accessible via the "Events & Presentations" section of the Investors area on the website.
  • Dial-in numbers are (800)-343-4136 for domestic callers & (203) 518-9843 for international callers, with Conference ID BIOATLA.
  • BioAtla operates as a global clinical-stage biotechnology company with facilities in San Diego, California, & Beijing, China via a partnership with BioDuro-Sundia.
  • The company utilizes its proprietary Conditionally Active Biologic (CAB) platform to develop reversibly active monoclonal & bispecific antibodies for solid tumors.
  • CAB product candidates are designed for selective targeting, greater efficacy, lower toxicity, & cost-efficient manufacturing compared to traditional antibodies.
  • BioAtla maintains over 780 active patent matters, including more than 500 issued patents, covering methods of making, screening, manufacturing, & composition of matter.
  • Internal contact for inquiries is CFO Richard Waldron, while external media inquiries should be directed to Joyce Allaire at LifeSci Advisors, LLC.